- Home
- LSAK vs AUTL Comparison
LSAK vs AUTL Comparison
Compare LSAK & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSAK | AUTL |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | South Africa | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 431.2M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LSAK | AUTL |
|---|---|---|
| Price | $4.91 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 85.2K | ★ 1.4M |
| Earning Date | 05-06-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $659,701,000.00 | $10,120,000.00 |
| Revenue This Year | $14.35 | $669.62 |
| Revenue Next Year | $8.60 | $79.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.92 | ★ 496.00 |
| 52 Week Low | $3.40 | $1.11 |
| 52 Week High | $5.54 | $2.70 |
Technical Indicators
Market Signals| Indicator | LSAK | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 31.66 |
| Support Level | $4.38 | N/A |
| Resistance Level | $5.54 | $1.52 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 37.56 | 8.11 |
Price Performance
Historical ComparisonAbout LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.